Angelini Pharma
As of the edition of 20 October 2026, Angelini Pharma runs 8 drugs, 6 of them marketed; it is on route A at 1 target and on route B at 2 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
- Catalyst Pharmaceuticals, Inc.: acquired in 2026; successor Angelini Pharma S.p.A
Drugs by status
| Status | Count |
|---|---|
| Marketed | 6 |
| Went quiet | 2 |
| Total | 8 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Perampanel | Ended 2026 (patent) | 4 |
| Trazodone | Ends 2029 (patent) | 1 |
| Cenobamate | Ends 2032 (patent) | 0 |
| Amifampridine | Ends 2029 (exclusivity) | 0 |
| Vamorolone | Ends 2040 (patent) | 4 |
| Dapiprazole | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 2 targets.
All 3 rows on route A or B
In the product3 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 3 targets where Angelini Pharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Inherited and neonatal: 3 trials led
- Nervous system: 2 trials led
- Blood and lymph: 1 trials led